Renalytix announced that the Federal Medicare Administrative Contractor (MAC) National Government Services (NGS) has initiated payment of claims for KidneyIntelX testing for patients with Medicare coverage.

Four presentations, including first clinical utility findings from multi-year real world evidence results from a major healthcare system underscore value of KidneyIntelX™ platform in improving cost economics for Medicare population.

98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b.

Data shared in oral presentation at American Diabetes Association 82nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cause of death in patients with diabetes and chronic kidney disease

Renalytix announced the successful completion of $30.0 million financing package

Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all Renalytix healthcare provider partners

Renalytix announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director.

Positive Study Results Published for KidneyIntelXTM in Monitoring Patient Response to New Drug Therapy

Seventh KidneyIntelX implementation partnership for Renalytix focused on underserved populations with high disease burden